Oral News and Research

RSS

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Enzo Biochem Inc. announced today that favorable results of the Company’s clinical trial for treatment of non-alcoholic steatohepatitis (NASH) were presented at the annual meeting of the American Association for the Study of Liver Diseases. The study was a randomized double blind placebo controlled format of EGS21, Enzo’s orally administered beta glucosylceramide formulation, designed to evaluate safety and efficacy of the study drug in patients with NASH and its associated metabolic syndrome.

2 Nov 2009

Extending hepatitis C treatment for liver transplant patients results in sustained viral clearance

Extending hepatitis C treatment for liver transplant patients beyond current practice results in high rates of clearance of the hepatitis C virus from the blood, as well as a low rate of relapse, according to a Henry Ford Hospital study.

2 Nov 2009

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

More than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response (SVR) with a telaprevir-based regimen according to results of an intent-to-treat (ITT) analysis announced today by Vertex Pharmaceuticals Incorporated.

2 Nov 2009

Sosei and ASKA Pharmaceuticals sign distribution agreement

Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, has entered into a definitive distribution agreement with ASKA Pharmaceuticals Co., Ltd. ("ASKA", TSE First Section Index: 4514) for the commercialisation of the emergency contraceptive pill SOH-075 (NorLevo(R)).

2 Nov 2009

Study: Charcoal lessens atherosclerotic lesions in mice with kidney damage

Charcoal may provide a new approach to managing the high rate of heart disease in patients with advanced kidney disease, according to preliminary research being presented at the American Society of Nephrology's 42nd Annual Meeting and Scientific Exposition in San Diego, CA.

2 Nov 2009

Shire to present key data on ADHD treatments at national psychiatric meeting

Shire plc, the global specialty biopharmaceutical company, announced today that it will present key scientific data on its Attention-Deficit/Hyperactivity Disorder (ADHD) treatments, INTUNIV- (guanfacine) Extended Release Tablets, Vyvanse- (lisdexamfetamine dimesylate) Capsules CII, and Daytrana- (methylphenidate transdermal system) CII, at a national meeting of psychiatrists to be held October 27 - November 1 in Honolulu.

31 Oct 2009

Shire announces Phase IIIb study results of Daytrana

Shire plc, the global specialty biopharmaceutical company, today announced findings at a major medical meeting from a Phase IIIb study of the tolerability and effectiveness of Daytrana® (methylphenidate transdermal system) in adolescents aged 13 to 17 years diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD).

31 Oct 2009

Colgate-Palmolive reaches ‘100 Million Smiles’ goal with its oral health education program

Colgate-Palmolive Company, the world leader in oral care, announced this week that it has reached 100 million children in the United States, providing free dental screenings, oral health education and treatment referrals as part of its ongoing national education program Colgate Bright Smiles, Bright Futures®.

31 Oct 2009

Shire announces third quarter 2009 financial results

Shire plc, the global specialty biopharmaceutical company, announces results for the three months to September 30, 2009.

31 Oct 2009

Accuray to focus on its CyberKnife Robotic Radiosurgery System at the ASTRO meeting

Accuray Incorporated, a global leader in the field of radiosurgery, announced today that 28 CyberKnife-focused abstracts have been accepted as part of the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO), taking place November 1 - 5 in Chicago, Illinois. This represents a 27 percent increase in CyberKnife abstracts over last year's Annual Meeting.

31 Oct 2009

FDA approves Covidien's Abbreviated New Drug Application for CII

Covidien, a leading global provider of healthcare products, today announced that its subsidiary, Mallinckrodt Inc., has received U.S. Food and Drug Administration (FDA) approval of its Abbreviated New Drug Application (ANDA) for Oral Transmucosal Fentanyl Citrate (CII).

31 Oct 2009

New York Times examines debate over U.S. global health spending priorities

The New York Times examines the "debate over whether the United States and other rich nations spend too much on AIDS, which requires lifelong medications, compared with diarrhea and the other leading killer of children, pneumonia, both of which can be treated inexpensively."

30 Oct 2009

Researchers report an epidemic of sexually-transmitted HCV infection among HIV-infected men in NY City

Researchers in New York City are reporting their work uncovering a new epidemic of hepatitis C virus (HCV) infection among men-who-have-sex-with-men (MSM) who have HIV infection.

30 Oct 2009

Repros Therapeutics signs settlement agreement with major creditors

Repros Therapeutics today announced that the Company has entered into a settlement agreement with its major creditors for the large majority of the debt incurred associated with the recently suspended Proellex® clinical program.

30 Oct 2009

AcelRx Pharmaceuticals completes End-of-Phase 2 meeting with the FDA for its ARX-01drug/device

AcelRx Pharmaceuticals, Inc. today announced that it has successfully completed an End-of-Phase 2 meeting with the FDA for ARX-01, a drug/device combination product based on the company's proprietary NanoTab(TM) dosage form, which enables delivery of sufentanil by the non-invasive oral transmucosal (sublingual) route.

30 Oct 2009

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that it has implemented a staffing plan to operate the company that anticipates licensing its lead development programs and resuming development of earlier stage product candidates.

30 Oct 2009

Cumberland Pharmaceuticals and Phebra team up to commercialize Caldolor injection

Cumberland Pharmaceuticals Inc. and Phebra Pty Ltd., an Australian-based specialty pharmaceutical company, today announced they have entered into an exclusive partnership for the commercialization of Caldolor® (ibuprofen) Injection in Australia and New Zealand.

30 Oct 2009

Girls' ethnicity and weight linked to participation in risky sexual behaviors

A University of Pittsburgh study sheds new light on the relationship between race, body weight and sexual behavior among adolescent girls. The results suggest that a girl's ethnicity and her actual weight or perception of her weight may play a role in her participation in risky sexual behaviors. The study results are published in the November issue of Pediatrics, now available online.

29 Oct 2009

Procter & Gamble reports net sales of $19.8 billion for the July - September quarter

The Procter & Gamble Company (NYSE: PG) reported net sales of $19.8 billion for the July - September quarter which exceeded the Company's guidance.

29 Oct 2009

Positive results from Genta's Phase 3 trial of Genasense

Genta Incorporated today announced top-line results from AGENDA, the Company’s Phase 3 trial of Genasense® (oblimersen sodium) Injection in patients with advanced melanoma. AGENDA is a randomized, double-blind, placebo-controlled trial of dacarbazine administered with or without Genasense® in patients who have not previously received chemotherapy.

29 Oct 2009

Oral News and Research

Enzo Biochem announces results of EGS21 clinical trial for treatment of non-alcoholic steatohepatitis

Extending hepatitis C treatment for liver transplant patients results in sustained viral clearance

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

Sosei and ASKA Pharmaceuticals sign distribution agreement

Study: Charcoal lessens atherosclerotic lesions in mice with kidney damage

Shire to present key data on ADHD treatments at national psychiatric meeting

Shire announces Phase IIIb study results of Daytrana

Colgate-Palmolive reaches ‘100 Million Smiles’ goal with its oral health education program

Shire announces third quarter 2009 financial results

Accuray to focus on its CyberKnife Robotic Radiosurgery System at the ASTRO meeting

FDA approves Covidien's Abbreviated New Drug Application for CII

New York Times examines debate over U.S. global health spending priorities

Researchers report an epidemic of sexually-transmitted HCV infection among HIV-infected men in NY City

Repros Therapeutics signs settlement agreement with major creditors

AcelRx Pharmaceuticals completes End-of-Phase 2 meeting with the FDA for its ARX-01drug/device

ARYx Therapeutics to complete an out-licensing agreement for clinical development and commercialization of budiodarone

Cumberland Pharmaceuticals and Phebra team up to commercialize Caldolor injection

Girls' ethnicity and weight linked to participation in risky sexual behaviors

Procter & Gamble reports net sales of $19.8 billion for the July - September quarter

Positive results from Genta's Phase 3 trial of Genasense

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News